BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:MGD024 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of MGD024\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05362773-3108@assetmemo.bio
DTSTAMP:20261121T005233Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:MGD024: Phase 1 readout est. (NCT05362773)
DESCRIPTION:MGD024\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study of M
 GD024 in Patients With Relapsed or Refractory Hematologic Malignancies\nEs
 timated primary completion: November 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/mgd024#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05362773
URL:https://assetmemo.bio/drug/mgd024#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
